Clinical and regulatory implications of the cardiac arrhythmia suppression trial
- 1 January 1990
- journal article
- editorial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 65 (1) , 103-105
- https://doi.org/10.1016/0002-9149(90)90034-x
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: A dangerous imbalance in the risk-benefit ratioAmerican Heart Journal, 1989
- The Cardiac Arrhythmia Suppression Trial (CAST)New England Journal of Medicine, 1989
- Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression after Myocardial InfarctionNew England Journal of Medicine, 1989
- Clinical Characteristics of Patients with Ventricular Fibrillation during Antiarrhythmic Drug TherapyNew England Journal of Medicine, 1988
- Risk factors for the development of proarrhythmic eventsThe American Journal of Cardiology, 1987
- Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainideJournal of the American College of Cardiology, 1986
- Alterations in regional myocardial distribution and arrhythmogenic effects of aprindine produced by coronary artery occlusion in the dogCardiovascular Research, 1981